ClinicalTrials.gg
CompletedNCT01507857Updated Nov 28, 2013

An Efficacy Trial in Inactivated Enterovirus Type 71 (EV71) Vaccine

A Phase 3 interventional study of 400U /0.5ml EV71 vaccine and 0/0.5ml placebo in Hand, Foot and Mouth Disease, sponsored by Sinovac Biotech Co., Ltd. Completed at 3 sites in China. Open to participants aged 6 Months to 35 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-11-28.

Sponsored by Sinovac Biotech Co., Ltd · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
10,077
Allocation
Randomized
Ages
6 Months to 35 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Hand, Foot and Mouth Disease by Sinovac Biotech Co., Ltd — 4 open to participants now, 4 under way, 2 of them phase 3. Hand, Foot and Mouth Disease · Sinovac Biotech Co., Ltd.

Enrollment
2nd of 15
10,077 · median 744
Started
2012
with 1 other
Phase 3
5 of 20
2 open now
Registered
2nd of 20
by date

Among the 20 studies in Hand, Foot and Mouth Disease by Sinovac Biotech Co., Ltd, this one is the 2nd largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2012, is one of 5 in phase 3, and was the 2nd registered.

Hand, Foot and Mouth Disease

59 studies on the registry are indexed under Hand, Foot and Mouth Disease; 10 are open to participants now.

Browse Hand, Foot and Mouth Disease studies →

Open to participants now

4 of the 20 studies in Hand, Foot and Mouth Disease by Sinovac Biotech Co., Ltd are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 4 Hand, Foot and Mouth Disease studies recruiting now, 1 sets no upper age limit and 3 stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 6 Months to 35 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Hand, Foot and Mouth Disease by Sinovac Biotech Co., Ltd, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, immunogenicity and safety of EV71 Vaccines in preventing Hand, Foot and Mouth disease caused by EV71 in a total 10,000 healthy infants volunteers aged from 6 to 35months old.

Read the detailed description

The phase II study of inactivated vaccine (vero cell) against EV71 has completed on Dec 2011 in China. The data from the phase I and II study suggested that the inactivated EV71 vaccine had a clinically acceptable safety and good immunogenicity for healthy Chinese infants. In order to evaluate the efficacy of the vaccine against Hand, Foot and Mouth disease caused by EV71, and to further explore the safety profile of this vaccine in expending infant population, a phase III clinical trial is planed to conduct.

03

Conditions studied

  • Hand, Foot and Mouth Disease

Keywords

  • EV71 vaccine
  • HFMD
  • efficacy
  • EV71 associated disease
04

Who can participate

Ages eligible
6 Months to 35 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males and females, aged from 6 months to 11 years old Health is determined by medical history, physical examination, laboratory examination and clinical judgment of the investigator
  • Provided legal identification for the sake of recruitment
  • Subjects and/or parent(s)/legal guardian(s) are able to understand and sign informed consents

Exclusion criteria

Exclusion Criteria:

  • History of Hand-foot-mouth Disease
  • Subject that has allergic history of vaccine, or allergic to any ingredient of vaccine
  • Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
  • Congenital malformations or developmental disorders, genetic defects, or severe malnutrition
  • Epilepsy, seizures or convulsions history, or family history of mental illness
  • disease or immunodeficiency, or parents, brothers and sisters have autoimmune diseases or immunodeficiency
  • History of asthma, angioedema, diabetes or
  • History of thyroidectomy or thyroid disease that required medication within the past 12 months
  • Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
  • Asplenia, functional asplenia or any condition resulting in the absence or removal the spleen
  • Acute illness or acute exacerbation of chronic disease within the past 7 days
  • Any history of medications or cytotoxic medications or inhaled within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)
  • History of any blood products within 3 months
  • Administration of any within 14 days
  • Administration of subunit or inactivated vaccines ,e.g., pneumococcal vaccine, or allergy treatment within 7 days
  • Axillary temperature > 37.0 centigrade before vaccination
  • Abnormal laboratory parameters before vaccination
  • Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a to protocol participation or impairs a volunteer's ability to give
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
10,077 participants (actual)

Study arms

  • Experimental
    400U /0.5ml in infants

    inactivated vaccine(vero cell) against EV71 of 400U /0.5ml in 5000 infants aged 6-35 months old on day0,28

    Biological: 400U /0.5ml EV71 vaccine

  • Placebo comparator
    0/0.5ml placebo in infants

    0/0.5ml placebo in 5000 infants aged 6-35 months old on day0,28

    Biological: 0/0.5ml placebo

Interventions

  • Biological400U /0.5ml EV71 vaccine

    Drug page: Enterovirus 71 vaccine

    inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval

    Also known as: EV71 vaccine

  • Biological0/0.5ml placebo

    0/0.5ml placebo, two doses, 28 days interval

    Also known as: placebo

06

What researchers measure

Primary outcomes

  1. The incidence rate of Hand, Foot and Mouth disease caused by EV71 within one year observation period after the second vaccination

    to evaluate the efficacy of EV71 vacccine against HFMD caused by EV71

    Time frame: From 28 days after the second vaccination to one year

Secondary outcomes

  1. The GMT of anti-EV71 antibodies in serum after second vaccination

    to evaluate the GMT of anti-EV71 antibodies in serum 28 days after second vaccination

    Time frame: 28 days after first vaccination

  2. The GMT of anti-EV71 antibodies in serum 7 and 13 months after second vaccination

    to evaluate the immune persistence of anti-EV71 antibodies in serum

    Time frame: 7 and 13 months after second vaccination

  3. Frequency of systemic and local adverse reactions after the first vaccination

    Frequency of systemic and local adverse reactions in healthy infants following first doses of EV71 vaccine

    Time frame: 28 days after the first vaccination

  4. Frequency of systemic and local adverse reactions after the second vaccination

    Frequency of systemic and local adverse reactions in healthy infants following second doses of EV71 vaccine

    Time frame: 28 days after the second vaccination

07

Study locations

3 sites
  • Ganyu
    Lianyungang, Jiangsu, China
  • Taixing
    Taizhou, Jiangsu, China
  • Sheyang CDC
    Yancheng, Jiangsu, China
08

References and documents

Publications

  • Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, Tan X, Wang L, Mao Q, Wu J, Hu Y, Ji T, Song L, Liang Q, Zhang B, Gao Q, Li J, Wang S, Hu Y, Gu S, Zhang J, Yao G, Gu J, Wang X, Zhou Y, Chen C, Zhang M, Cao M, Wang J, Wang H, Wang N. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014 Feb 27;370(9):818-28. doi: 10.1056/NEJMoa1304923. PubMed 24571754 ↗
  • Chong P, Hsieh SY, Liu CC, Chou AH, Chang JY, Wu SC, Liu SJ, Chow YH, Su IJ, Klein M. Production of EV71 vaccine candidates. Hum Vaccin Immunother. 2012 Dec 1;8(12):1775-83. doi: 10.4161/hv.21739. Epub 2012 Sep 19. PubMed 22992566 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2012
First posted
Jan 11, 2012
Start
Jan 2012
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Last update
Nov 28, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01507857
Responsible party
Sponsor
First posted
Jan 11, 2012
Start date
Jan 2012
Primary completion
Mar 2013
Completion
Mar 2013
Last update
Nov 28, 2013

Study contacts

Hua Wang, BS
principal investigator · Jiangsu Center for Diseases Control and Prevention

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enterovirus 71 vaccine

Start the discussion